Transcatheter Patent Foramen Ovale Closure: Real World Data From a Tertiary Hospital

Drakopoulou, Maria; Trantalis, George; Simopoulou, Chryssa; Katsaros, Odysseas; Korovesis, Theofanis; Oikonomou, George; Papanikolaou, Angelos; Aggeli, Constadina; Tsioufis, Κonstantinos; Toutouzas, Konstantinos

doi:10.1016/s0735-1097(23)01330-x

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 23 Despite the smaller sample size and shorter follow‐up compared with other reports, our experience shows that AF incidence is ≈5%. 24 Goldsweig et al showed a high incidence (11.9%) in a retrospective cohort from 2006 to 2019; interestingly, a significant proportion of patients undergoing PFO closure (namely, 17.6%) had preexisting AF. 25 A recent meta‐analysis of 45 studies showed an overall incidence rate of 0.013 patient‐years.…”

Section: Incidence Of Postprocedural Afmentioning

confidence: 97%

Atrial Fibrillation After Patent Foramen Ovale Closure: Incidence, Pathophysiology, and Management

Apostolos,

Tsiachris,

Drakopoulou

et al. 2024

JAHA

Self Cite

View full text Add to dashboard Cite

This comprehensive review explores the incidence, pathophysiology, and management of atrial fibrillation (AF) following percutaneous closure of patent foramen ovale (PFO). Although AF is considered a common adverse event post PFO closure, its incidence, estimated at <5%, varies based on monitoring methods. The review delves into the challenging task of precisely estimating AF incidence, given subclinical AF and diverse diagnostic approaches. Notably, a temporal pattern emerges, with peak incidence around the 14th day after closure and a subsequent decline after the 45th day, mimicking general population AF trends. The pathophysiological mechanisms behind post PFO closure AF remain elusive, with proposed factors including local irritation, device‐related interference, tissue stretch, and nickel hypersensitivity. Management considerations encompass rhythm control, with flecainide showing promise, and anticoagulation tailored to individual risk profiles. The authors advocate for a personalized approach, weighing factors like age, comorbidities, and device characteristics. Notably, postclosure AF is generally considered benign, often resolving spontaneously within 45 days, minimizing thromboembolic risks. Further studies are required to refine understanding and provide evidence‐based guidelines.

show abstract

Section: Incidence Of Postprocedural Afmentioning

confidence: 97%